|
Jun 24
|
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
|
|
Jun 22
|
3 No-Brainer Stocks to Buy for Under $100 Right Now
|
|
Jun 22
|
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
|
|
Jun 21
|
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
|
|
Jun 21
|
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
|
|
Jun 20
|
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
|
|
Jun 18
|
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
|
|
Jun 18
|
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
|
|
Jun 18
|
Bristol Myers Squibb Announces Dividend
|
|
Feb 17
|
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
|
|
Feb 17
|
Bristol-Myers Squibb Company (NYSE:BMY) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
|
|
Feb 15
|
Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
|
|
Feb 14
|
Bristol Myers is Tapping US High-Grade Bond Market to Fund M&A
|
|
Feb 14
|
Bristol Myers Squibb Recommends Stockholders Reject "Mini-Tender" Offer by Tutanota LLC
|
|
Feb 14
|
Bristol Myers Sees Over $85 Billion of Demand for M&A Bond Sale
|
|
Feb 14
|
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
|
|
Feb 14
|
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
|
|
Feb 12
|
A Look at Pharma ETFs After Q4 Earnings
|
|
Feb 12
|
7 Dividend Stocks to Buy at a 52-Week Low
|
|
Feb 12
|
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
|